In good news for India’s healthcare sector especially in high-risk cardiac and liver transplant surgeries,  Plasmagen Biosciences Private Limited (Plasmagen), a Bengaluru-based biopharmaceutical company, has partnered with global biotechnology leader CSL Behring to introduce Haemocomplettan P (Human Fibrinogen Concentrate) to the Indian market.

The move hopes to address the challenge of managing uncontrolled massive bleeding given that India performs approximately 1,50,000 cardiac surgeries and around 1,800 liver transplants annually, with a substantial number of these patients requiring blood transfusions to manage hemorrhage.

In fact, around 50 per cent of cardiac surgery patients need blood transfusions, and more than 25 per cent of blood transfusions in hospitals are for liver transplant recipients. Delayed control of bleeding in these surgeries can lead to severe complications, including renal failure, stroke, and even death, as well as increased healthcare costs and longer hospital stays.

Vinod Nahar, Managing Director of Plasmagen, highlighted that the collaboration with CSL Behring not only addresses the pressing issue of bleeding management in critical surgeries but also expands the scope of treatment options across various medical specialties, including cardiac, liver transplant, gastroenterology, and pediatrics. This partnership ensures that high-quality, globally recognised biopharmaceutical products are available in India, aiming to improve healthcare outcomes, enhance disease awareness, and provide comprehensive patient education, he added.

Haemocomplettan P, manufactured by CSL Behring, is a specialised product designed to treat and prevent bleeding disorders in patients with congenital afibrinogenemia and acquired hypofibrinogenemia.

This human fibrinogen concentrate has been used globally for over 27 years, treating more than 3.5 lakh patients and demonstrating significant efficacy in rapidly restoring fibrinogen levels.

This replenishment is crucial for effective blood clotting and can significantly reduce the need for blood transfusions. Dr N Kanagarajan, a Senior Consultant Cardiac Anaesthesiologist at the Madras Medical Mission in Chennai, said.